Skip to content

Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery

Pre- and Post-operative Compared to Post-operative Only Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06159777
Enrollment
74
Registered
2023-12-07
Start date
2024-06-05
Completion date
2026-03-13
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, Prolapse; Female, Surgical Procedure, Unspecified

Keywords

postoperative constipation, minimally invasive surgery, apical prolapse, prolapse

Brief summary

The goal of this clinical trial is to test the use of a laxative before surgery in women having surgery to fix pelvic prolapse that do not have constipation. The main question it aims to answer is: Does use of a laxative before surgery lessen the discomfort of bowel movements after surgery? Participants will be asked to complete questionnaires before and after surgery. Researchers will compare using the laxative before and after surgery versus only after surgery to see if there is less discomfort with bowel movements after surgery.

Detailed description

The purpose of this study is to evaluate if there is a difference in bother related to constipation between a pre-operative versus post-operative start of a bowel regimen for patients undergoing surgery for pelvic organ prolapse This will be a multi-institution, single-blind, randomized control trial utilizing questionnaires and chart review to evaluate effect of pre-operative bowel regimen on post-operative constipation. 1. Study team and surgeons will be blinded to group assignments, participants will not be. 2. Participants will be randomized after consent is obtained, and at least 1 week prior to planned surgery, via computer-generated blocks in a 1:1 ratio between study group (pre-operative and post-operative use) and control group (post-operative only use) of polyethylene glycol 3350 (PEG)

Interventions

DRUGPolyethylene Glycol 3350

\*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.

Sponsors

University Hospitals Cleveland Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Patients assigned female sex at birth undergoing an apical prolapse procedure including: sacrocolpopexy, sacrospinous ligament suspension, uterosacral ligament suspension, or colpocleisis. Planned urogynecologic procedure may include hysterectomy, adnexectomy, colporrhaphy, perineorrhaphy, or treatment of stress urinary incontinence. * Planning to undergo primary procedure as above via minimally invasive route: vaginal or laparoscopic (including robotic-assisted). Including those that have an unplanned conversion intraoperatively of minimally invasive route to open laparotomy.

Exclusion criteria

* Diagnosis of irritable bowel syndrome, inflammatory bowel disease, slow transit constipation, obstructed defecation, or symptomatic constipation at time of study screening and recruitment. (Slow transit constipation and obstructed defecation defined as per American Gastroenterological Association 2013 constipation statement. Symptomatic constipation defined as any of the following: Bristol Stool Scale score of 1 or 2, PAC-SYM score greater than 1.0, self-reported 2 or less bowel movements per week.) * Current use of pharmacologic laxative agent ≥1x/week (prescription or OTC) for the treatment of constipation symptoms * Allergy or intolerance to polyethylene glycol 3350 * Planning to undergo surgery via laparotomy * Scheduled for any concurrent non-urogynecologic procedure, ex abdominoplasty * History of large bowel resection, surgical treatment of constipation, or anal sphincter surgery * History of sacral neuromodulation * Current or prior radiation therapy to the abdomen or pelvis * Current or prior diagnosis of malignancy * Unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
PAC-SYMPre-operative, 1 week post-operative, 2 weeks post-operativePatient assessment of constipation symptoms (PAC-SYM) is a validated 12-item questionnaire with reported average score 0-4.

Secondary

MeasureTime frameDescription
PAC-QOL: Patient assessment of constipation quality of life measurePre-operative, 2 weeks post-operative
Time to first bowel movement1 week post-operativeafter surgery in approximate hours/days
Doses of PEG used1 week post-operative, 2 weeks post-operativepolyethylene glycol 3350 (PEG) doses of 17 grams powder mixed in 8oz of liquid
Rescue laxative use1 week post-operative, 2 weeks post-operativeUse of additional laxatives or enemas
Satisfaction with pain after surgery1 week post-operativeSatisfaction with pain after surgery

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDavid Sheyn, MD

University Hospitals Cleveland Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026